HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 8, 2014, Pages 1441-1449

  Zhang, Jun ^a   Chen, Ning ^a,b   Qi, Juan ^a   Zhou, Baosen ^a   Qiu, Xueshan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

ADAM9; HDGF; Lung cancer; Molecular staging biomarker; Prognostic biomarker

Indexed keywords

ADAM PROTEIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HEPATOMA DERIVED GROWTH FACTOR; PROTEIN ADAM9; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904331012     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1687-2     Document Type: Article

References (32)

1. Besse B, Chevalier TL (2008) Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect? JCO 26:5014-5017
2. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C (2005) The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26:17-24
3. Douillard JY, Gauducheau CR (2010) Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. JCO 28(1):3-5
4. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105:567-575 (Pubitemid 30146503)
5. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A (2004) Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 286:L1194-L1201 (Pubitemid 38656655)
6. Fritzsche FR, Jung M, Tölle A et al (2008a) ADAM9 Expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 54:1097-1106
7. Fritzsche FR, Wassermann K, Jung M et al (2008b) ADAM9 is highly expression in renal cell cancer and is associated with tumour progression. BMC Cancer 8:179
8. Grutzmann R, Luttges J, Sipos B et al (2004) ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 90:1053-1058 (Pubitemid 38495828)
9. Iwasaki T, Nakaqawa K, Nakamura H, Takada Y, Matsui K, Kawahara K (2005) Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 13:1075-1080
10. Liu Q, Zhang J (2013) Abnormal expression of GLO1 in non-small cell lung cancer. Zhongguo Yike Daxue Xuebao 42:77-78 (In Chinese)
11. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei A (2008) Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584-594 (Pubitemid 351720831)
12. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717
13. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF (1995) Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 60:466-472
14. O'Shea C, Mckie N, Buggy Y et al (2003) Expression of ADAM9m RNA and protein in human breast cancer. Int J Cancer 105:754-761 (Pubitemid 36706097)
15. Ren H, Tang X, Lee JJ et al (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. JCO 22:3230-3237 (Pubitemid 41103677)
16. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
17. Tannapfel A, Anhalt K, Hausermann P et al (2003) Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 201:238-249 (Pubitemid 37258935)
18. Uyama H, Tomita Y, Nakamura H et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12:6043-6048 (Pubitemid 44703767)
19. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M (2001) Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37:2264-2274 (Pubitemid 33001299)
20. Xie Y, Minna JD (2010) Non-small-cell lung cancer mRNA expression signature predicting response to adjuvant chemotherapy. JCO 28:4404-4407
21. Yamamoto S, Tomita Y, Hoshida Y et al (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12:117-122 (Pubitemid 43166184)
22. Yamamoto S, Tomita Y, Hoshida Y et al (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14:2141-2149 (Pubitemid 46988256)
23. Zhang J, Mao L (2006) SiRNA targeting hepatoma-derived growth factor (HDGF) inhibits growth of non-small cell lung cancer in xenograft models. Tumor Biology 35: Emerging Molecules, Mechanisms, and Models. Proc Amer Assoc Cancer Res 47:abstract #5135
24. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L (2006) Downregulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66:18-23 (Pubitemid 43166002)
25. Zhang J, Qi J, Guo Y et al (2011a) Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14:211-218 (In Chinese)
26. Zhang J, Qi J, Guo Y (2011b) Abnormal expression and clinical significance of HDGF and ADAM9 in non-small cell lung cancer. Zhongguo Yike Daxue Xuebao 40:280-281 (In Chinese)
27. Zhang J, Qi J, Chen N, Guo Y, Fu W, Zhou B, He A (2011c) Highly expressed ADAM9 in completed resected stage I non-small cell lung cancer cases predicts a shortened survival. J Thorac Oncol 6:s1068-s1069
28. Zhang J, Chen N, Qi J (2013a) HDGF, ADAM9 involved in a novel pathway of cell growth and invasion of non-small cell lung cancer cells, may become novel molecular staging biomarkers, prognostic and predictive biomarkers of NSCLC. J Thorac Oncol 8:s753
29. Zhang J, Qi J, Chen N, Fu W, Zhou B, He A (2013b) High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer. Oncol Lett 5:1461-1466
30. Zhou Y, Zhou N, Fang W, Huo J (2010) Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn Pathol 5:58
31. Zhu CQ, Ding K, Strumpf F et al (2010) Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. JCO 28:4417-4424
32. Zubel A, Flechtenmacher C, Edler L, Alonso A (2009) Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix. Gynecol Oncol 114:332-336